{"classes":[{"categories":[{"measurements":[{"comment":"not enough events to calculate","groupId":"OG000","lowerLimit":"3.5","upperLimit":"NA","value":"12.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Time to progression (TTP) was defined as the number of months between the start of treatment to the first documentation of disease progression. Disease progression was determined using IMWG-URC as assessed by the investigator. The same censoring rules, except for death, as in analysis of PFS were applied in the calculation of TTP.\n\nParticipants who died prior to progressive disease were censored at the date of last evaluable response assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.","id":"OG000","title":"Phase 2 300 mg 2/7 Schedule"}],"paramType":"MEDIAN","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Day 1 up to 14.1 months","title":"Kaplan-Meier Estimate for Time to Progression (TTP) as Assessed by Investigator During Phase 2","type":"SECONDARY","unitOfMeasure":"months"}